The Company s announcement (RNS Number: 9835M) of 27 January 2021 (the Announcement ) misstated the terms of the of Broker Warrants issued to the Company s broker Brandon Hill Capital Limited as part of their remuneration in relation to the Placing.
In error, the Announcement stated that Brandon Hill Capital Limited would receive a warrant over 750,000 new ordinary shares in the Company which could be exercised at a price of 3.0p per share at any time up to 3 February 2024.
Brandon Hill Capital Limited was entitled to receive a warrant over 2,500,000 new ordinary shares in the Company which may be exercised at a price of 2.0p per share at any time up to 3 February 2024.
(3)
NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as
in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I-IV programs. Multiple IND s, NDA/BLA filings and/or defense and multiple successful launches.
Share:
NEW YORK and LONDON, Jan. 13, 2021 (GLOBE NEWSWIRE) Tiziana Life Sciences plc (NASDAQ:TLSA) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as
in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. Multiple IND s, NDA/BLA filings and/or defense and multiple successful launches.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of Prospectus
Tiziana Life Sciences PlcDecember 18, 2020 GMT
This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferable securities referred to in this announcement except on the basis of information contained in the prospectus (the “Prospectus”) in its final form that is published by Tiziana Life Sciences plc in connection with the admission of the Company’s ordinary shares (the “Ordinary Shares”) to listing on the standard segment of the Official List of the Financial Conduct Authority (the “FCA”) and to trading on the main market for listed securities (the “Main Market”) of
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of Prospectus
This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferable securities referred to in this announcement except on the basis of information contained in the prospectus (the Prospectus ) in its final form that is published by Tiziana Life Sciences plc in connection with the admission of the Company s ordinary shares (the Ordinary Shares ) to listing on the standard segment of the Official List of the Financial Conduct Authority (the FCA ) and to trading on the main market for listed securities (the Main Market ) of London Stock Exchange plc (the London Stock Exchange ). This announcement is not an offer to sell, or a solicitation of an offer to acquire, securities in the U